Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy — SINCERE

Esophageal Squamous Cell Carcinomas Clinical Trial

Official title:
Salvage Immunotherapy Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE Study)

Status Not yet recruiting

Clinical Trial Summary

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of esophageal squamous cell carcinoma patients nonresponding to initial neoadjuvant chemoradiotherapy. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinomas

Clinical Trial Details

NCT number	NCT05103501
Study type	Interventional
Source	Shanghai Chest Hospital
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	December 1, 2021
Completion date	September 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02611700` - Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma	Phase 3
Not yet recruiting	`NCT05621707` - Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)	Phase 2
Recruiting	`NCT04741490` - Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery	N/A
Recruiting	`NCT05022654` - SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.	Phase 2